Safety of ALK Ragweed Tablet

A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00330083

Enrollment

Registered

2006-05-25

Start date

2006-05-31

Completion date

Unknown

Last updated

2007-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Interventions

BIOLOGICALALK Ragweed Tablet

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Ragweed pollen induced rhinoconjunctivitis * Adults of either sex (18-50 years of age) * Positive skin prick test to ragweed

Exclusion criteria

* Previous treatment with immunotherapy

Design outcomes

Primary

Measure	Time frame
Assessment of safety by recording of adverse events	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026